Wall Street brokerages predict that Recro Pharma Inc (NASDAQ:REPH) will announce sales of $19.97 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Recro Pharma’s earnings, with estimates ranging from $18.70 million to $21.88 million. Recro Pharma posted sales of $18.28 million in the same quarter last year, which suggests a positive year over year growth rate of 9.2%. The business is expected to announce its next earnings results on Wednesday, November 6th.
According to Zacks, analysts expect that Recro Pharma will report full year sales of $93.82 million for the current fiscal year, with estimates ranging from $92.50 million to $95.75 million. For the next fiscal year, analysts anticipate that the firm will post sales of $101.41 million, with estimates ranging from $96.60 million to $105.32 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow Recro Pharma.
Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.29. The firm had revenue of $31.26 million for the quarter, compared to analyst estimates of $24.06 million. Recro Pharma had a negative net margin of 64.26% and a negative return on equity of 472.45%.
Several equities analysts have commented on the stock. Oppenheimer set a $20.00 price objective on shares of Recro Pharma and gave the company a “buy” rating in a report on Friday, August 9th. BidaskClub raised shares of Recro Pharma from a “buy” rating to a “strong-buy” rating in a research report on Friday. Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Thursday, August 15th. Finally, ValuEngine raised shares of Recro Pharma from a “hold” rating to a “buy” rating in a research report on Friday, May 24th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Recro Pharma has a consensus rating of “Buy” and an average target price of $12.70.
A number of large investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. lifted its holdings in shares of Recro Pharma by 191.1% during the first quarter. Meeder Asset Management Inc. now owns 5,086 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 3,339 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Recro Pharma during the second quarter worth about $48,000. Bessemer Group Inc. purchased a new stake in shares of Recro Pharma during the second quarter worth about $57,000. Virtu Financial LLC grew its position in shares of Recro Pharma by 27.7% during the first quarter. Virtu Financial LLC now owns 12,875 shares of the specialty pharmaceutical company’s stock worth $75,000 after purchasing an additional 2,795 shares in the last quarter. Finally, Paloma Partners Management Co purchased a new stake in shares of Recro Pharma during the second quarter worth about $109,000. Institutional investors own 62.99% of the company’s stock.
Shares of NASDAQ:REPH traded down $0.29 on Friday, hitting $12.04. The company had a trading volume of 134,300 shares, compared to its average volume of 297,268. Recro Pharma has a 1-year low of $5.53 and a 1-year high of $12.67. The stock has a market cap of $272.30 million, a price-to-earnings ratio of -4.84 and a beta of -0.27. The stock has a 50 day moving average price of $10.32 and a 200 day moving average price of $9.21.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Further Reading: Why do companies issue convertible shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.